The potential for ischemic preconditioning to reduce infarct size was first recognized more
than 30 years ago [180]. Despite extension of the concept to ischemic postcondition‑ing …

Ischaemic heart disease is one of the leading causes of morbidity and mortality worldwide.
The development of cardioprotective therapeutic agents remains a partly unmet need and a …

Nitroxyl anion (HNO/NO−), the one-electron reduced form of nitric oxide (NO), induces
positive cardiac inotropy and selective venodilation in the normal in vivo circulation. Here we …

Over the past century, HNO research has evolved from fundamental physical examinations
to elucidation of interactions in atmospheric, industrial and bacterial processes. Most …

Nitric oxide (NO) participates in the control of contractility and heart rate, limits cardiac
remodeling after an infarction and contributes to the protective effect of ischemic pre-and …

Until recently, most of the biological effects of nitric oxide (NO) have been attributed to its
uncharged state (NO), yet NO can also exist in the reduced state as nitroxyl (HNO or NO−) …

The redox siblings nitroxyl (HNO) and nitric oxide (NO) have often been assumed to
undergo casual redox reactions in biological systems. However, several recent studies have …

Nitroxyl (HNO), the 1-electron reduced and protonated congener of nitric oxide (NO), has
received recent attention as a potential pharmacological agent for the treatment of heart …

A series of brief (a few minutes) ischemia/reperfusion cycles (ischemic preconditioning, IP)
limits myocardial injury produced by a subsequent prolonged period of coronary artery …

M1 macrophages enter a glycolytic state when endogenous nitric oxide (NO) reprograms
mitochondrial metabolism by limiting aconitase 2 and pyruvate dehydrogenase (PDH) …